Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887306 | 0.94 | ME2 (0.42) | EPHX2KMT2AMEN1CYP2C19SMN1; SMN2 | |
| SCHEMBL5887405 | 0.94 | SMN1; SMN2 (0.42) | EPHX2KMT2AMEN1CYP2C19SMN1; SMN2 | |
| SCHEMBL5886891 | 0.93 | TP53 (0.44) | CTNNB1TCF7L2KMT2AMEN1CYP2C19 | |
| SCHEMBL5886869 | 0.92 | HIF1A (0.47) | EPHX2KMT2AMEN1PTGER4 | |
| SCHEMBL5886889 | 0.92 | MAPK10 (0.45) | MAPK14EPHX2KMT2AMEN1CYP2C19 | |
| SCHEMBL5886763 | 0.92 | SMN1; SMN2 (0.42) | MAPK14EPHX2KMT2AMEN1CYP2C19 | |
| SCHEMBL5886867 | 0.92 | BRAF (0.48) | CTNNB1TCF7L2MAPK14EPHX2KMT2A | |
| SCHEMBL5887146 | 0.91 | CTNNB1 (0.43) | CTNNB1TCF7L2MAPK14EPHX2KMT2A | |
| SCHEMBL5886912 | 0.91 | ME2 (0.43) | MAPK14EPHX2KMT2AMEN1CYP2C19 | |
| SCHEMBL5886791 | 0.91 | ENPP2 (0.48) | CTNNB1TCF7L2EPHX2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | CTNNB1 1452/4885TCF7L2 381/4885MAPK14 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.